Synendos Therapeutics
Basel, Switzerland· Est. 2017
Synendos Therapeutics advances selective endocannabinoid reuptake inhibitors to restore ECS balance, developing new treatments for anxiety, PTSD and mood disorders.
Private Company
Total funding raised: $19.3M
About
Synendos Therapeutics advances selective endocannabinoid reuptake inhibitors to restore ECS balance, developing new treatments for anxiety, PTSD and mood disorders.
Small Molecules
Funding History
2Total raised:$19.3M
Series A$15MJan 15, 2023
Seed$4.3MMar 15, 2021